On Thursday, the US Food and Drug Administration approved remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease.
"A lot of people were worried about the supply and wanted to keep remdesivir for their worst-case patients."
The WHO did not comment on the FT report, saying the results of its study were not yet public.
The drug is used for its ability to hinder the virus's ability to reproduce, and has been attributed to shorter hospital stays for patients receiving it in trials.
Trump received a single eight-gram dose of Regeneron's polyclonal antibody cocktail, REG-COV2, Conley said, and the company confirmed in a statement sent to "The Jerusalem Post."
The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases.
The drug was authorized in May for use in patients with a severe form of the illness, after trial data showed the antiviral drug helped shorten hospital recovery time.
Several hospitals, including Sheba Medical Center at Tel Hashomer and Rambam Medical Center in Haifa, had reported they were out.
“We are trying to get a hold of it,” Sheba Medical Center’s Galia Rahav told The Jerusalem Post. She said the US President Donald Trump “bought all of it and one of it is left for the whole world.”
"We need leaders to make these hard decisions about distributing based on equity, not just on market-driven factors."